Advances in the Phenotyping and Management of Common Variable Immunodeficiency.

Mikaela E Gill¹, Aditi Jogdand¹, Caroline Schissel², Mei-Sing Ong³, Sara Barmettler⁴, Jocelyn R Farmer⁵

¹Clinical Immunodeficiency Program, Beth Israel Lahey Health, Division of Allergy & Immunology, Lahey Clinic, Burlington, MA, USA.

²Translational Research Program, Division of Allergy & Immunology, Lahey Clinic, Burlington, MA, USA.

³Computational Health Informatics Program, Boston Children's Hospital, Boston, MA, USA.

⁴Division of Rheumatology, Allergy, and Immunology, Massachusetts General Hospital, Boston, MA, USA.

⁵Clinical Immunodeficiency Program, Beth Israel Lahey Health, Division of Allergy & Immunology, Lahey Clinic, Burlington, MA, USA; Department of Medicine, UMass Chan Medical School, Lahey Clinic, Burlington, MA, USA. Electronic address: jocelyn.farmer@lahey.org.

PubMed DOI

Abstract

This article highlights advances in the phenotyping and management of common variable immunodeficiency (CVID). Advances in phenotyping include the use of cell-based, soluble, and genetic profiling, combined with novel applications like machine learning, to better define high-risk (complicated CVID) and low-risk (uncomplicated CVID) patient populations. Advances in management include first-in-class…

Create a free account to keep reading

Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.

Create Free Account Sign In

Want unlimited research access? See Pro plans

Data Accuracy Notice: Research intelligence on Health AI Central is aggregated from public sources (PubMed, ClinicalTrials.gov, FDA, NIH, CMS, and others) and refreshed nightly. Classifications and derived metrics are produced by automated methods described in our Methodology. We recommend verifying critical data points against the primary sources before making decisions.